<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">4408</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url">http://dx.doi.org/10.31782/IJCRR.2022.14607</article-id><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>&#13;
	Emerging Implementation of Nano-Suspension Technology for Delivery of Poorly Soluble Drug for the Treatment of Helminths Disease&#13;
&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mantry</surname><given-names>Shubhrajit</given-names></name></contrib><contrib contrib-type="author"><name><surname>Shinde</surname><given-names>Shubham</given-names></name></contrib><contrib contrib-type="author"><name><surname>Shaikh</surname><given-names>Sahil</given-names></name></contrib><contrib contrib-type="author"><name><surname>Joshi</surname><given-names>Sumit</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dama</surname><given-names>Ganesh</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>15</day><month>03</month><year>2022</year></pub-date><volume>)</volume><issue/><fpage>43</fpage><lpage>50</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>&#13;
	Anthelmintics are medications that are used to treat parasitic worm infections. This comprises flatworms like flukes and tapeworms as well as roundworms like nematodes. They are critical for human tropical medicine. Nano-suspensions are one of the many applications of nanotechnology. Nano-suspensions are liquid formulations that feature submicron colloidal dispersion of pharmaceutical active component particles stabilised by surfactants. Nano-suspension technology is a novel and cost-effective method for improving the bioavailability of hydrophobic medicines, particularly those that are poorly soluble in aqueous solutions. Nano-suspensions play a significant role in the development of new medication formulations. High-pressure homogenizers, emulsion solvent evaporation, melt emulsification technique, and nanoprecipitation are all used to make nano-suspensions. Particle size, zeta potential, drug content, and in vitro drug dissolution were all examined for the nano-suspensions. Poorly soluble drugs can benefit from nano-suspension technology to improve their stability and bioavailability. The bioavailability of nano-suspension was also tested in mice, which showed that the particle size distribution of nano-suspension was considerably affected by bioavailability. The rate of anthelmintic nano-suspension dissolution was substantially higher than that of raw drug powder. In vivo pharmacokinetic characteristics of nano-suspension indicated a substantial increase in Cmax and AUC(0-t) when compared to pure drug. When compared to pure drug bioavailability, anthelmintic nano-suspension had a greater oral bioavailability.&#13;
&#13;
</p></abstract><kwd-group><kwd>Helminths</kwd><kwd> Nano-suspension</kwd><kwd> Parasites</kwd><kwd> Bioavailability</kwd><kwd> In vitro study</kwd><kwd> Solubility</kwd></kwd-group></article-meta></front></article>
